<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709579</url>
  </required_header>
  <id_info>
    <org_study_id>MODULCORTICOATROPHIE</org_study_id>
    <secondary_id>2007-A00675-48</secondary_id>
    <nct_id>NCT00709579</nct_id>
  </id_info>
  <brief_title>Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids</brief_title>
  <official_title>Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermo Cosmetique</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Paul Sabatier of Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Européen de Recherche sur la Peau,</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre BIOMETRIE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Dermo Cosmetique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methodology :Phase III study, single centre, double blind, versus excipient, randomised,&#xD;
      controlateral design.&#xD;
&#xD;
      Selection of the patients :Number of subjects required 60 :&#xD;
&#xD;
        -  30 patients needing an oral corticotherapy&#xD;
&#xD;
        -  30 patients needing a topical corticotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study conduct&#xD;
&#xD;
      Two steps for each patient:&#xD;
&#xD;
        1. the first step lasting 3 months : assessment of changes in mechanisms involved in ACIC&#xD;
           with the RV3391A cream (M0 à M3). At the beginning of the corticotherapy, each patient&#xD;
           will apply RV3391A on anterior side of a forearm and the placebo on the other side&#xD;
           (randomised) for 3 months.&#xD;
&#xD;
           Clinical exam and objective measurements will be realised.&#xD;
&#xD;
           This step will allow us to describe and compare the evolution of cutaneous atrophy's&#xD;
           markers produced by glucocorticoïds markers between M0 and M3:&#xD;
&#xD;
             -  between topical and oral corticotherapy&#xD;
&#xD;
             -  between RV3391A and the placebo.&#xD;
&#xD;
        2. the second step, the cohort follow-up, leading off the end of the first step (M3 à M24)&#xD;
           The period of the second step will depend on the progression of patient's disease and on&#xD;
           the period of his medical follow-up. This period may lasting until the 24th month after&#xD;
           the inclusion in the study.&#xD;
&#xD;
      The patients will not apply RV3391A and the placebo anymore. They will be followed-up in the&#xD;
      CHU.Assessments of the cutaneous atrophy's markers produced by glucocorticoïds will be&#xD;
      realised at M6, M12, M18 and M24 with non invasive methods (clinical scoring, imaging,&#xD;
      extensometry) to exactly describe on a long-term period the evolution of the ACIC. The&#xD;
      assessments on forearm having received the placebo will allow us to know natural history of&#xD;
      skin atrophy induced by corticotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20 Mhz echography : Dermal Thickness</measure>
    <time_frame>M0 versus M3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>20 Mhz echography : Dermal Thickness</measure>
    <time_frame>M0 versus M6, M12, M18, M24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherent Tomography : Epidermal Thickness</measure>
    <time_frame>M0, M1, M3, M6, M12, M18, M24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frosch Score</measure>
    <time_frame>M0, M1, M3, M6, M12, M18, M24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutometry: assessment of the skin mechanical properties</measure>
    <time_frame>M0, M1, M3, M6, M12, M18, M24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology: study of skin layers and assessment of collagen and other proteins.</measure>
    <time_frame>M0, M3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistology and molecular biology: assessment of CD44, HB-EGF and erbB1, cutaneous cytokines, filaggrin, corneodesmosin and involucrin.</measure>
    <time_frame>M0, M3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peeling with an adhesive tape: sample of superficial epidermis layers and assessment by biochemical and immunodetection methods of anti-desmoglein, anti-kallikrein 7 and anti-corneodesmosin antibodies</measure>
    <time_frame>M0, M3,</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cortico Atrophy</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RV3391A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV3391A</intervention_name>
    <description>A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.</description>
    <arm_group_label>RV3391A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients needing an oral corticotherapy:&#xD;
&#xD;
               -  aged over 50 years&#xD;
&#xD;
               -  first corticotherapy over 0.5 mg/kg/day&#xD;
&#xD;
               -  expectable period with a corticotherapy over 10 mg/day more than 3 months&#xD;
&#xD;
               -  having signed a written informed consent form&#xD;
&#xD;
               -  registered with a social security or health insurance system&#xD;
&#xD;
          -  Patients needing a topical corticotherapy:&#xD;
&#xD;
               -  aged over 50 years&#xD;
&#xD;
               -  topical corticotherapy with a high or very high potency corticoid over 10 g/day&#xD;
&#xD;
               -  expectable period with a topical corticotherapy more than 3 months&#xD;
&#xD;
               -  having signed a written informed consent form&#xD;
&#xD;
               -  registered with a social security or health insurance system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Oral or topical corticotherapy within the last 3 months&#xD;
&#xD;
          -  Cutaneous inflammation on the anterior side of the forearm&#xD;
&#xD;
          -  Medical history of psychosis induced by corticotherapy&#xD;
&#xD;
          -  Medical history of allergy to RV3391A product its and excipients.&#xD;
&#xD;
          -  Medical history of allergy to mineral cream Avene SPF50 excipients.&#xD;
&#xD;
          -  Medical history of allergy to latex, surgical tape, chlorhexidine, lidocaine or&#xD;
             xylocaine&#xD;
&#xD;
          -  Clotting disorder or anticoagulant intake&#xD;
&#xD;
          -  Healing disorder&#xD;
&#xD;
          -  Women who are not post-menopausal women&#xD;
&#xD;
          -  Substitutive estrogenotherapy for less than 6 months&#xD;
&#xD;
          -  Impossibility to be registered in the Volunteers National Register&#xD;
&#xD;
          -  Inability to comply with requirements of the clinical monitoring program,&#xD;
&#xD;
          -  Inability to personally sign the informed consent form&#xD;
&#xD;
          -  Is deprived of his freedom by an administrative or judicial decision; or who is under&#xD;
             guardianship or protective custody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Sailler, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Marie Schmitt, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Dermo Cosmetique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carle Paul, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hopitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>June 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <last_update_submitted>July 3, 2008</last_update_submitted>
  <last_update_submitted_qc>July 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anne-Marie SCHMITT</name_title>
    <organization>Pierre Fabre Dermo Cosmetique</organization>
  </responsible_party>
  <keyword>Patients needing an oral corticotherapy</keyword>
  <keyword>Patients needing a topical corticotherapy</keyword>
  <keyword>Corticotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

